# Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade

Source: https://onco.cc/key-papers/paper-cd47-pancreatic-pharmacol-res-2022/  
OnCo record `paper-cd47-pancreatic-pharmacol-res-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Review on CD47 in Pancreatic ductal adenocarcinoma, in Pharmacological research (2022), one of the most cited Europe PMC records with CD47 in its title.

## Summary

A daily increase in the number of new cases of pancreatic ductal adenocarcinoma remains an issue of contention in cancer research. The data revealed that a global cumulated case of about 500, 000 have been reported. This has made PDAC the fourteenth most occurring tumor case in cancer research. Furthermore, PDAC is responsible for about 466,003 deaths annually, representing the seventh prevalent type of cancer mortality. PDAC has no salient symptoms in its early stages. This has exasperated several attempts to produce a perfect therapeutic agent against PDAC. Recently, immunotherapeutic research has shifted focus to the blockade of checkpoint proteins in the management and of some cancers. Investigations have centrally focused on developing therapeutic agents that could at least to a significant extent block the SIRPα-CD47 signaling cascade (a cascade which prevent phagocytosis of tumors by dendritic cells, via the deactivation of innate immunity and subsequently resulting in tumor regression) with minimal side effects. The concept on the blockade of this interaction as a possible mechanism for inhibiting the progression of PDAC is currently being debated. This review examined the structure--function activity of SIRPα-CD47 interaction while discussing in detail the mechanism of tumor resistance in PDAC. Further, this review details how the blockade of SIRPα-CD47 interaction serve as a therapeutic option in the management of PDAC.

Indexed on Europe PMC as PubMed record 35597384 (DOI 10.1016/j.phrs.2022.106264). Its title names CD47 and its text names Pancreatic ductal adenocarcinoma; PubMed types it as a review (Review). It was matched automatically to the idea "Can MYC be drugged directly, and will patients tolerate it?" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Pharmacological research
- Year: 2022
- DOI: 10.1016/j.phrs.2022.106264
- Authors: Alausa A, Lawal KA, Babatunde OA, et al.
- What it means: One of the most cited reviews Europe PMC returns for CD47 in Pancreatic ductal adenocarcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by CD47 in the title and Pancreatic ductal adenocarcinoma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; A review summarises other studies; the primary reports it cites are the evidence.

## Sources

- Pharmacol Res 2022: https://doi.org/10.1016/j.phrs.2022.106264
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35597384/
- Europe PMC: https://europepmc.org/article/MED/35597384

## Connected records

- ideas: [Can MYC be drugged directly, and will patients tolerate it?](https://onco.cc/ideas/idea-drugging-myc/), [Engineered bacteria that live in tumours and manufacture drugs there](https://onco.cc/ideas/idea-bio2-engineered-bacteria-payloads/), [Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours](https://onco.cc/ideas/idea-moon-cold-to-hot-programme/)

---
JSON: https://onco.cc/api/v1/entities/paper-cd47-pancreatic-pharmacol-res-2022.json